OssDsign reports exceptional data from the clinical study TOP FUSION
Uppsala, January 9, 2024. OssDsign AB (publ.) today announces that positive data from the clinical study TOP FUSION has been submitted to a peer-reviewed scientific journal. Top-line results show a 93 % spinal fusion rate at 12 months as assessed with CT by independent radiological review from Medical Metrics Inc. after surgery with the novel nanosynthetic bone graft OssDsign Catalyst.The data indicates that the use of OssDsign Catalyst leads to consistent and rapid bone healing and remodeling, with improved patient outcomes as a result. They also confirm the previously reported best-in-